Novo Nordisk Surges On Wegovy Win, Eyes Bullish Rebound Near 52-Week Lows

While Novo recently lowered its 2025 sales growth forecast to 8-14% from 13-21%, the approval could help stabilize sentiment and reignite momentum. Read Also: How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment Novo Nordisk A/S NVO may have found a timely catalyst. From the lows of its 52-week trading range, the Danish drugmaker is showing signs that a bullish comeback might be on the horizon—driven by both regulatory approval momentum and technically solid ma ...